Partnering opportunity

Bioinformatics based platform enabling precision medicine, nutrition and cosmetics through the discovery of biomarkers

Summary

A Greek SME has developed a platform enabling precision medicine, nutrition and cosmetics through the discovery of biomarkers, which focuses on analysis of complex life-science and biological data. This solution expedites the prognosis and diagnosis process for certain diseases through the isolation of biomarkers, which are confidently related to the cause of the disease. The Greek SME is looking for partners to cooperate with under commercial, financial or research cooperation agreement.

Partner sought

Commercial agreement with technical assistance: The company provides a cloud-driven suite of bioinformatics tools, able to integrate biological data from various sources and provide comprehensive results and meaningful knowledge to biology researchers. Potential partners are organisations conducting molecular biology related research such as pharmaceuticals companies. Financial Agreement: The company has initiated, this year, a Seed funding round for the further development of the provision platform and the commercialization of its own experimental verified biomarkers. Company is looking for funds in the area of health and personalised medicine with connections to pharmaceuticals companies and clinical research organisations specialised in pre-clinical and clinical trials. Research cooperation agreement: The company offers biological data analytics (bioinformatics) services towards the discovery of biomarkers. This R&D services can be utilised by R&D departments, research laboratories and applied research companies activated in the industry of pharmaceutics, nutrition and cosmetics.

Description

A Greek SME is a bioinformatics pioneer company in precision medicine, nutrition and cosmetics, which focuses on providing computational frameworks and tools for the analysis of complex life-science and biological data. The most significant bottleneck of research in biotechnology, personalized medicine, pharma & personalized nutrition is the identification of accurate prognostic, diagnostic and therapeutic biomarkers which will enable the physicians to diagnose a forthcoming disease and treat it appropriately in a personalized manner before the disease affects the patient’s life or otherwise predict the impact of drugs and nutritional products at molecular level. The company’s approach is unique and it is able to expedite prognosis and diagnosis process for certain diseases through the isolation of fewer, more relevant and prioritized integrated biomarkers, which are confidently related to the cause of the disease; contrary to current methods which only relate to its symptoms. The company proved able to reduce time and costs of extracting predictive biomarkers to 1/6 and 1/8 respectively. The company’s suite of products consists of cloud-driven bioinformatics tools, able to integrate biological data from various sources and provide comprehensive results and meaningful knowledge (early stage biomarkers of high quality & biological systemic interpretation) using advanced big-data-oriented artificial intelligence methods and tools. The suite is tested by more than 400 users. Research and industry collaborative projects are also part of the process of getting the suite known. Targeted end users in the health, nutrition and cosmetic industries are the R&D departments of bio-pharma, nutrition, cosmetics & applied research companies who need bioinformatics tools & services but also molecular biology and bioinformatics academics. In more detail, end users target groups are universities, biology labs, medical/biological devices companies, while pharmaceuticals, contract research organizations, medical practitioners, hospital labs, IT companies and bio-statisticians can either be end users target groups or strategic partners. Partners sought are basically from the industry of pharmaceutics, nutrition and cosmetics that conduct molecular biology research for their product’s design and pre-clinical and clinical trials. The company is looking for partners to cooperate with under commercial, financial or research cooperation agreement.

Advantages and innovations

Company’s technology offers unique inside path to an integrated end-to-end accurate biomarker discovery process, simultaneous integration of data from different sources and has demonstrated ability to locate significantly more common proteins in large scale proteomics datasets. The solutions are based on biological networks modelling to integrate complex biological information in many layers and advanced big data-oriented artificial intelligence methods The company owns •Patented method for assigning functional annotation to all molecules and predicting physical protein-protein interactions •RNA sequencing analysis pipeline that maximizes non-coding RNA discovery (patent pending) •Network based biomarker discovery pipeline able to locate the cause of diseases instead of their results (patent pending) •DNA sequencing analysis pipeline that locates only disease related mutations and ranks them with severity score (patent pending). Current bioinformatics products are either embedded to experimental instruments or standalone tools and platforms. Both categories of competitors provide limited functionalities for an overwhelming cost and require hardware equipment and expertise for installation and usage. Bioinformatics companies offering software applications rely mainly on statistical analysis The suite is able to expedite prognosis and diagnosis process for diseases as well as the prediction of the impact of certain drugs and nutrition products in health at the molecular level through the isolation of much fewer, more relevant integrative biomarkers related to the cause of the disease and not its symptoms-as current methods do. Using the suite, biology researchers can save time and money while reassuring high performance and robustness in their data analysis. Precision medicine may also contribute to the reduction of releases of antibiotics and other pharmaceutical active substances into the environment, delivering additional benefits to the wider society

Development stage

Already on the market

Intellectual Property Rights (IPR)

Patent(s) applied for but not yet granted


Register your interest

How it works

  • Tell us about yourself
  • We’ll discuss with you
  • We put the right partners in touch

EEN help you find the right partner, rather than you going it alone.

Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.

These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.

Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.

?What value does EEN add?
This is your pitch: remember to include your unique selling points (USP) and why someone would want to do business with you
Tell us why you are a good fit for this opportunity, and why you think you're the right people for this partnership
If there's anything additional, or commercially sensitive you'd like to know about this opportunity, please let us know

When you entered your email address above, we emailed you a code to verify you're human and have access to that account.

?What's this?

What next?

To finish up, we just need some extra details about you and your company